Cell Cycle

2'-O-Me-cAMP is a cAMP analogue that selectively stimulates exchange proteins activated by cAMP (Epac). This compound serves as a valuable tool for studying cAMP-mediated signaling pathways and the role of Epac in various biological processes. Its low membrane permeability can provide insights into the mechanisms of cAMP action in cellular contexts.

SCH-53870 is a Ras activation inhibitor that specifically binds to the Ras-GDP complex, thereby maintaining Ras in an inactive GDP-bound state and inhibiting its activation to the GTP-bound form. This compound modulates cell signaling pathways and subsequently affects cell proliferation by obstructing Ras activation. SCH-53870 is applicable in cancer research, providing a valuable tool for studying Ras-related oncogenic mechanisms.

NY-0173 is an antagonist of exchange proteins directly activated by cAMP (EPAC), demonstrating IC50 values of 3.5 μM for EPAC2 and 4.0 μM for EPAC1. This reagent serves as a valuable tool for investigating the biological roles and pathways mediated by EPAC. Researchers can utilize NY-0173 to explore its impact on cellular processes influenced by EPAC signaling.

ARN25062 is a potent inhibitor targeting CDC42 and RHOJ, demonstrating significant antitumor activity. This novel trisubstituted pyrimidine derivative is suitable for research applications investigating the modulation of cell signaling pathways involved in cancer progression and metastasis. Its specific inhibition of CDC42 and RHOJ makes it a valuable tool for studying cellular processes related to tumorigenesis.

Goralatide is a Ra activator that modulates the thermal sensitivity of hematopoietic progenitor cells. It enhances the disparity in thermal sensitivity between leukemia progenitor cells and normal hematopoietic progenitor cells, thereby increasing the efficacy of hyperthermia therapy. This compound is relevant for research in cancer treatment strategies, particularly those involving targeted thermal therapies.

Sp-8-pCPT-2'-O-Me-cAMPS is a selective activator of the exchange protein directly activated by cyclic AMP (EPAC). This compound enhances EPAC-mediated signaling pathways, playing a significant role in the regulation of various physiological processes. It is valuable for research into endocrine metabolism and related signaling mechanisms.

CDK7 ligand 2 is a selective inhibitor targeting CDK7, a crucial cyclin-dependent kinase involved in transcription regulation. This compound exhibits significant potential in drug discovery and development, particularly in the synthesis of PROTACs (Proteolysis Targeting Chimeras). Its application in research may facilitate novel therapeutic approaches for diseases associated with abnormal transcriptional control.

CDK9 ligand 4 functions as a potent ligand for cyclin-dependent kinase 9 (CDK9). This compound is instrumental in the design and development of PROTAC-based degraders, facilitating targeted degradation of CDK9 proteins, which plays a crucial role in transcriptional regulation and HIV-1 infection research. CDK9 ligand 4 contributes significantly to studies aimed at therapeutic strategies against viral infections and dysregulated transcriptional processes.

CDK4 Degrader 1 (ML 1–71) is a molecular glue degrader that specifically targets cyclin-dependent kinase 4 (CDK4). This compound promotes the selective degradation of CDK4, leading to reduced cell proliferation and induction of cell cycle arrest in various cancer models. It serves as a valuable tool for investigating CDK4's role in tumorigenesis and for the development of targeted therapies in cancer research.

PROTAC CDK9 degrader-4 is a potent CDK9 degradation agent that facilitates the targeted degradation of cyclin-dependent kinase 9. This compound effectively modulates transcriptional regulation by harnessing the power of PROTAC technology, leading to significant biological activity in various cellular contexts. It holds potential applications in cancer research and the study of transcriptional control mechanisms.

PROTAC DYRK2 degrader 1 is a selective degrader targeting DYRK2, functioning through the ubiquitin-proteasome system. It exhibits DC50 values of 1.607 μM in MDA-MB-231 cells and 3.265 μM in HeLa cells, effectively inducing DYRK2 degradation. This compound is valuable for research focused on triple-negative breast cancer and cervical cancer, facilitating the exploration of targeted protein degradation mechanisms in these malignancies.

HZ1 is a selective inhibitor of cyclin-dependent kinase-like 3 (CDKL3) that operates via targeted inhibition of this kinase. It demonstrates significant tumor-suppressive activity and has potential to circumvent resistance to CDK4/6 inhibitors. This compound is applicable in cancer research, particularly in studies focused on cell cycle regulation and therapeutic resistance mechanisms.

Ribociclib succinate is an orally active inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), functioning through ATP-competitive mechanisms. It demonstrates potent activity with IC50 values of 10 nM and 39 nM against CDK4 and CDK6, respectively, while exhibiting over 1,000-fold selectivity against the cyclin B/CDK1 complex. This selectivity makes it a valuable tool in cancer research, particularly in studies targeting cell cycle regulation and therapeutic strategies for hormone receptor-positive breast cancer.

Ribociclib succinate hydrate is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), functioning through competitive inhibition of ATP binding. With IC50 values of 10 nM and 39 nM against CDK4 and CDK6, respectively, it demonstrates significant selectivity over the cyclin B/CDK1 complex. This compound is utilized in cancer research, particularly in studies focusing on cell cycle regulation, tumor proliferation, and the therapeutic potential in various malignancies. Its ability to cross the blood-brain barrier allows for exploration in central nervous system-related cancers.

PROTAC CDK2-pRb degrader-1 is an orally active PROTAC that targets cyclin-dependent kinase 2 (CDK2) for degradation. This compound effectively inhibits the phosphorylation of retinoblastoma protein (Rb) at serine 807/811 by promoting the ubiquitination and proteasomal degradation of CDK2. Demonstrating significant biological activity with EC50 values of 12 nM and 125 nM in human cells, PROTAC CDK2-pRb degrader-1 is particularly useful in research focused on CCNE1-amplified cancers, including ovarian, gastric, and breast cancers, as it inhibits tumor growth and induces tumor stasis in xenograft models.